4. The affidavit required by this section may be taken before any magistrate, justice of the peace, or commissioner for taking affidavits for use in any court of the province or British possession in which such affidavit is taken, or, in the case of a foreign country, before a British consul or vice-consul.

5. Any officer shall, when required to do so by any regulation made in that behalf by the Minister, act as an inspector of proprietary and patent medicines and shall procure and submit samples thereof for the purpose of comparison or analysis.

6. Every sample so obtained by an officer shall be transmitted to the Minister for examination, analysis and comparison with the corresponding standard sample in the possession of the Minister.

7. All medicine shall be put up in packages or bottles, and every one of these, intended for sale or distribution in Canada, shall have the name and number under which it is registered, together with the manufacturer's name and address, placed upon it, which information shall be in conspicuous characters forming an inseparable part of the general label.

8. Each package or bottle shall, as soon as filled, have attached thereto an Inland Revenue stamp for an amount of duty varying according to the retail price of the medicine and container, as follows:—

25 cents and under	cents.
Over 25 cents and not exceeding 50 cents	"
Over 50 cents and not exceeding $1.00	"
Over $1.00	"

9. Six months after the coming into force of this Act such retail price must be plainly marked on each such package or bottle.

10. Except as herein otherwise provided, the stamps upon medicines manufactured in Canada shall be attached to the packages or bottles before the medicines leave the premises of the manufacturer. The stamps upon medicines imported shall be attached before they leave the custody of the proper customs house officers.

4. In case the result of an analysis shows that the medicine does not conform to the statement supplied by the manufacturer, compounder, proprietor or importer for sale in Canada, or is, in the opinion of the Minister, dangerous to health or life in the doses prescribed, or is for other reasons improper or unfit for sale, the Minister shall cause notice to be given to the manufacturer, compounder, properietor or importer for sale in Canada of such medicine, or to his agent or representative in Canada or in any province of Canada, of the result of such analysis, and shall name a time and place at which the said manufacturer, compounder, pro-